GATC

The New Standard for ROI: Using Predictive AI to Insure & De-Risk Biotech Investments

WEBINAR OVERVIEW

The economics of drug development are changing — and the most sophisticated players in biotech, pharma, and investment are paying close attention. This DIA webinar brings together the architects of a groundbreaking new financing model that is already live in the market, exploring how validated Predictive AI is fundamentally transforming how clinical trial risk is assessed, financed, and insured. For the first time, a non-dilutive, insurance-backed capital pathway — powered by GATC Health's proprietary Derisq™ AI Report and endorsed by Lloyd's of London through MCI Syndicate 1966 — is available to biotech companies seeking to advance their most promising clinical programs with less risk and less dilution. Panelists will examine the convergence of validated Predictive AI, institutional insurance underwriting, and a first-of-its-kind clinical trial financing structure — the Phase+ program — through the perspectives of the technology, the deal structure, the investment banking community, and real-world biotech operators.

This session is designed for investment banks, buy-side analysts, biotech CEOs, and investors who are navigating capital formation challenges and seeking a deeper understanding of how AI-validated assets are reshaping deal flow, due diligence, and fundraising dynamics in clinical-stage development. Attendees will leave with a clear understanding of what the Derisq™ AI Report delivers, why Lloyd's of London's endorsement matters, and how the Phase+ program creates a new lever for capital formation — all backed by independently validated AI with 86% sensitivity and 91% specificity, assessed under blinded conditions.

FEATURED TOPICS:

At the conclusion of this activity, participants should be able to:

Explain how GATC Health's Derisq™ AI Report uses multiomics-based biological simulation to predict drug candidate safety, efficacy, and off-target risk — and how its independently validated performance metrics (86% sensitivity, 91% specificity) translate to real-world clinical decision-making.
Describe the structure of the Phase+ program and how it combines GATC Health's AI diligence with Lloyd's-backed insurance through MCI to create a first-of-its-kind non-dilutive financing option for Phase 1, 2, and 3 clinical trials.
Articulate why Lloyd's of London's acceptance of GATC Health's AI platform as the basis for underwriting clinical trial risk represents a landmark validation signal for institutional investors and biotech stakeholders.
Discuss how sophisticated buy-side capital and institutional investors are beginning to incorporate AI-validated data into due diligence frameworks, and what this means for deal flow dynamics and asset valuation.
Evaluate how biotechs — including single-asset companies and those with multi-asset pipelines — can leverage the Phase+ program to reduce dilution, hedge development risk, and bring stronger evidence to partnership and fundraising conversations.
Identify how AI-validated assets are beginning to differentiate in BD&L and capital markets conversations, and why early adoption of Predictive AI validation may represent a structural competitive advantage.

Panelist Roster

Mark Flather

SVP, Business Development and Strategy, GATC Health

Mark Flather serves as Senior Vice President, Corporate Strategy and Business Development for GATC Health. Prior to joining GATC in January of 2026, Mr. Flather served as Senior Vice President, Corporate Strategy and Capital Markets for publicly traded Vistagen Therapeutics, Inc., a late-stage biopharmaceutical company developing novel therapeutics in the CNS space. Mr. Flather has more than 30 years of capital markets experience in various capacities on the buy-side, the sell-side and with two corporations in the healthcare industry. Prior to joining Vistagen in March 2021, Mr. Flather managed the Investor Relations and Corporate Communications for Adamis Pharmaceuticals, a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including allergy, opioid overdose, respiratory and inflammatory disease. While at Adamis, he was named on three different design patents for the company’s FDA-approved injection device platform. Prior to Adamis, Mr. Flather served as Vice President of Investor Relations and Outreach at MZ Group, a subsidiary of @titude Global, the world’s largest independent global IR consulting firm. Before MZ Group, Mr. Flather spent almost a decade as the Chief Operating Officer, Head Equity Trader, Investor Relations Director and Research Analyst for Hermes Advisors, a small to mid-cap equity hedge fund with an elite track record. Previously, he began his sell-side experience on the institutional sales and trading desk of the investment bank, Alex. Brown and Sons. Mr. Flather holds a B.A. in Psychology from U.C. Santa Barbara.

Dave Pfeiffer

SVP, Head of ARCAS, Bio-Tech, Acrisure Re

Dave represents the financing and deal-execution side of the Phase+ program. As the distribution and program management partner for this first-of-its-kind clinical trial financing structure, he brings a unique perspective on why this model was created, how it works in practice, and what it means for biotechs navigating capital formation challenges.

Erica Horwitz

Managing Director, Healthcare Investment Banking, RBC Capital Makets

Erica Horwitz is a Managing Director in the Healthcare Investment Banking Group at RBC Capital Markets. Previously, she led M&A at Bristol Myers Squibb, where she executed more than $25 billion in transactions, following nine years in investment banking at Barclays. She began her career at EY in Transaction Advisory Services. She earned her MBA and BA in Economics from the University of Michigan.

Moderated By:

Ty Lam

Chief Business Development Officer, GATC Health

Tyrone Lam is Chief Business Officer at GATC Health, a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. GATC Health’s Operon™ AI platform and its Derisq™ AI report are trusted by biopharma, researchers, investment firms, and the world’s largest insurance marketplace to assess and predict drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital.